H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Outlook Therapeutics (OTLK) to $3 from $30 and keeps a Buy rating on the shares. The firm updated the company’s model to give European Union and U.S. markets separate probabilities of success at 100% and 10%, respectively, due to the approval of ONS-5010 in the EU and the uncertainties in the U.S. approval.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OTLK:
- OTLK Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Outlook Therapeutics Reports Strong Earnings and Strategic Progress
- Outlook Therapeutics reports Q1 adjusted EPS (89c) vs. (78c) last year
- Outlook Therapeutics announces upcoming anticipated milestones
- Outlook Therapeutics Secures Funding and Board Restructures